Last reviewed · How we verify
Treatment C (treatment-c)
Treatment C, developed by Pfizer Inc., is a marketed drug with a revenue of $63.6B. It is used to treat Indication 1, Indication 2, and Indication 3. The drug's mechanism is not specified. Treatment C has undergone 100 trials and has been the subject of 1002 publications. Its commercial significance is substantial. There are no pipeline developments mentioned.
At a glance
| Generic name | treatment-c |
|---|---|
| Sponsor | Pfizer |
| Drug class | Not specified |
| Target | Not specified |
| Therapeutic area | Other |
| Phase | FDA-approved |
Approved indications
- Indication 1
- Indication 2
- Indication 3
Common side effects
Drug interactions
- Aspirin
- Warfarin
- Ibuprofen
- Clopidogrel
- Pentoxifylline
- Dipyridamole
- Ticlopidine
- Alteplase
- Urokinase
- Streptokinase
- Tenecteplase
- Rivaroxaban
Key clinical trials
- MK-4646 Multiple Dose Trial in Participants With Human Immunodeficiency Virus Type 1 (HIV-1) (MK-4646-003) (PHASE1)
- Therapy Adapted for High Risk and Low Risk HIV-Associated Anal Cancer (PHASE2)
- Nivolumab in Combination With Chemo-Immunotherapy for the Treatment of Newly Diagnosed Primary Mediastinal B-Cell Lymphoma (PHASE3)
- Venetoclax in Combination With ASTX727 for the Treatment of Chronic Myelomonocytic Leukemia and Other Myelodysplastic Syndrome/Myeloproliferative Neoplasm (PHASE2)
- BAL0891 in Patients With Advanced Solid Tumors or Relapsed or Refractory Acute Myeloid Leukemia (PHASE1)
- Pharmacokinetic and Subjective Effects of Heated Tobacco Products (NA)
- Testing the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinatumomab to the Usual Chemotherapy Treatment for Infants With Newly Diagnosed KMT2A-rearranged or KMT2A-non-rearranged Leukemia (PHASE2)
- Hyperpolarized Imaging in Diagnosing Participants With Glioma (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Treatment C CI brief — competitive landscape report
- Treatment C updates RSS · CI watch RSS
- Pfizer portfolio CI